# Four Drug Reinduction With Bortezomib for Relapsed or Refractory ALL or LL in Children and Young Adults

> **NCT02535806** · PHASE2 · TERMINATED · sponsor: **Children's Mercy Hospital Kansas City** · enrollment: 2 (actual)

## Conditions studied

- Acute Lymphoblastic Leukemia
- Lymphoblastic Lymphoma

## Interventions

- **DRUG:** Velcade
- **DRUG:** Methotrexate
- **DRUG:** Methotrexate / Hydrocortisone / Cytarabine
- **DRUG:** Dexamethasone
- **DRUG:** Mitoxantrone
- **DRUG:** Vincristine
- **DRUG:** Pegaspargase

## Key facts

- **NCT ID:** NCT02535806
- **Lead sponsor:** Children's Mercy Hospital Kansas City
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-07
- **Primary completion:** 2017-05-25
- **Final completion:** 2017-05-25
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** Funding source discontinued
- **Last updated:** 2019-08-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02535806

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02535806, "Four Drug Reinduction With Bortezomib for Relapsed or Refractory ALL or LL in Children and Young Adults". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02535806. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*